Abatacept Misses on Shingrix Response Save
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
Transcription
Hi. It's David Lu here reporting from Vienna, July 2024, here, obviously, in the Congress Hall, where a lot of good stuff has happened. I just wanna tell you a bit about a poster, which I'm a little bit late to, but I think gives a really important message. And I don't know why we're not talking about it a bit more. And this comes down to rheumatoid arthritis patients on abatacept and looking at their shin grips response.
Now, know that co stimulation is potentially important in forming that immunogenicity against a vaccine. And what have we seen in this is we actually saw in amongst the trial looking at Shingrix vaccination in patients treated with abatacept. The long and the short of it is that it's a bit disappointing, a bit scary. Because we saw that in terms of a humoral response, the antibody response, you had a modest increase in antibody titer. And, you know, at twelve weeks, we did have sixty four percent of people respond despite being on abatacept.
But that faded away through to twenty one percent at sixty weeks. And the titers are really disappointing. And then probably more pertinently, the cellular response, which we know is so important when it comes to vaccinating it against herpes zoster, was really a swing and a miss. And we really did not see any cellular response at all, basically. So I don't know what this means for abatacept treated patients.
We probably need to come up with some better strategies on how we're going to manage this. Should we be withholding abatacept in the lead up to vaccination to try and optimise that response? Are we going about this the right way? Are we relying on smarter heads? This poster was from Kevin Winthrop and Jeff Curtis and many other smart minds.
So I'm sure they're thinking about how to improve this for our Batisep patients so we don't leave them out in the cold when it comes to shingles. For plenty more on rheumatoid arthritis and everything else for rheumatology at YourLight twenty twenty four, you know where to go. Rheumatoid.com.
Now, know that co stimulation is potentially important in forming that immunogenicity against a vaccine. And what have we seen in this is we actually saw in amongst the trial looking at Shingrix vaccination in patients treated with abatacept. The long and the short of it is that it's a bit disappointing, a bit scary. Because we saw that in terms of a humoral response, the antibody response, you had a modest increase in antibody titer. And, you know, at twelve weeks, we did have sixty four percent of people respond despite being on abatacept.
But that faded away through to twenty one percent at sixty weeks. And the titers are really disappointing. And then probably more pertinently, the cellular response, which we know is so important when it comes to vaccinating it against herpes zoster, was really a swing and a miss. And we really did not see any cellular response at all, basically. So I don't know what this means for abatacept treated patients.
We probably need to come up with some better strategies on how we're going to manage this. Should we be withholding abatacept in the lead up to vaccination to try and optimise that response? Are we going about this the right way? Are we relying on smarter heads? This poster was from Kevin Winthrop and Jeff Curtis and many other smart minds.
So I'm sure they're thinking about how to improve this for our Batisep patients so we don't leave them out in the cold when it comes to shingles. For plenty more on rheumatoid arthritis and everything else for rheumatology at YourLight twenty twenty four, you know where to go. Rheumatoid.com.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.